v3.26.1
License Agreement, Advances From Collaboration Partners, Legal, and Other Contingencies (Detail) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Mar. 11, 2024
Oct. 31, 2025
Oct. 30, 2025
Jun. 30, 2023
Mar. 31, 2022
May 31, 2021
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2023
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2019
Mar. 31, 2025
Jan. 03, 2025
Jul. 10, 2024
Legal And Other Contingencies [Line Items]                                    
Aggregate milestone payment                 $ 470,000,000     $ 470,000,000            
Gain (loss) on fair value recognized                       100,000   $ (100,000)        
Research and development expense             $ 2,840,000 $ 898,000 4,500,000 $ 1,408,000   3,056,000 $ 3,577,000 8,598,000        
Clinical and regulatory milestone payments received                 3,600,000     3,600,000            
Patent Expenses Due To Harvard             100,000 100,000 100,000 100,000   100,000 100,000 100,000        
Debt Instrument, Unamortized Discount                       0            
Long term debt                       1,000,000            
Revenue from related party                       0 6,359,000 0        
2019 CFF Award [Member]                                    
Legal And Other Contingencies [Line Items]                                    
Other liabilities current                       12,100,000 12,100,000 12,100,000        
2022 CFF Award [Member]                                    
Legal And Other Contingencies [Line Items]                                    
Derivative liabilities                         100,000 100,000        
2021 CFF Award [Member]                                    
Legal And Other Contingencies [Line Items]                                    
Other liabilities current                       1,200,000 1,200,000 900,000        
Hercules Term Loan Agreement                                    
Legal And Other Contingencies [Line Items]                                    
Milestone Payments               500   500             $ 500,000  
Long term debt                                   $ 3,200,000
Elox - CFF [Member]                                    
Legal And Other Contingencies [Line Items]                                    
Other income                       1,200,000            
Royalty payment as percentage of net sales     1.00%                              
Royalties     $ 300,000                              
Elox - CFF [Member] | 2022 CFF Award [Member]                                    
Legal And Other Contingencies [Line Items]                                    
Aggregate milestone payment                         400,000 200,000        
Percentage Of Consideration Received For Disposition Event     10.00%                              
Elox - CFF [Member] | 2025 CFF Award [Member]                                    
Legal And Other Contingencies [Line Items]                                    
Value of the embedded derivative                       0            
Elox - CFF [Member] | Elox - Phase Two Clinical Development [Member] | 2022 CFF Award [Member]                                    
Legal And Other Contingencies [Line Items]                                    
Aggregate milestone payment       $ 200,000                            
Remaining amount of award payable upon achievement certain clinical development milestones                     $ 7,400,000              
Almirall License Agreement                                    
Legal And Other Contingencies [Line Items]                                    
Upfront payment received $ 3,000,000                                  
Aggregate milestone payment $ 470,000,000                                  
Total transaction price                       3,100,000            
Regulatory Milestone                         3,000,000          
Almirall License Agreement | License and Service [Member]                                    
Legal And Other Contingencies [Line Items]                                    
Revenue                         6,400,000          
Revenue from related party             0 0 0 0                
Cystic Fibrosis Foundation [Member]                                    
Legal And Other Contingencies [Line Items]                                    
Funding award amount received             0 0 0 0                
Royalty payment as percentage of net sales   1.00%                                
Royalties   $ 300,000                                
Debt Instrument, Unamortized Discount             300,000   300,000     300,000            
Cystic Fibrosis Foundation [Member] | 2025 CFF Award [Member]                                    
Legal And Other Contingencies [Line Items]                                    
Value of the embedded derivative                 0     $ 0            
Maximum [Member]                                    
Legal And Other Contingencies [Line Items]                                    
Related party transaction percentage of expenses                       5.00%            
Maximum [Member] | 2019 CFF Award [Member]                                    
Legal And Other Contingencies [Line Items]                                    
Funding award amount received                             $ 3,600,000      
Maximum [Member] | 2021 CFF Award [Member]                                    
Legal And Other Contingencies [Line Items]                                    
Funding award amount received           $ 2,600,000                        
Maximum [Member] | Elox - CFF [Member] | Elox - Phase Two Clinical Development [Member] | 2022 CFF Award [Member]                                    
Legal And Other Contingencies [Line Items]                                    
Award to fund development milestones         $ 15,900,000                          
Maximum [Member] | Almirall License Agreement                                    
Legal And Other Contingencies [Line Items]                                    
Regulatory Milestone                               $ 470,000,000    
Research and Development Agreements [Member]                                    
Legal And Other Contingencies [Line Items]                                    
Research and development grants received             0 $ 0 $ 0 0   $ 0 $ 0 0        
Repayment percentage of grants received                 100.00%       100.00%          
Royalty received including accrued LIBOR interest             $ 2,800,000   $ 2,800,000     2,800,000            
Research and Development Agreements [Member] | Israel Innovation Authority [Member]                                    
Legal And Other Contingencies [Line Items]                                    
Research and development grants received                 $ 2,600,000     2,600,000            
Technion Research and Development Foundation Ltd [Member]                                    
Legal And Other Contingencies [Line Items]                                    
Award to fund development milestones                   $ 6,500,000   6,500,000            
Research and development expense                       $ 100,000 $ 100,000 $ 100,000